Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

Study acronym: 4 PORT
StatusNot Yet Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints revised (3)
    • Primary endpoint revised
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In prolifertive diabetic retinopathy (PDR) eyes with bleeding known as vitreous hemorrhage (VH) requiring a surgical procedure to remove the vitreous, called a vitrectomy, we will determine if the benefit and safety of adding a small implant that will be filled with medication called Susvimo is better with limited laser treatment.
Trial Details
NCT Number NCT07864480
Lead Sponsor Southeast Retina Center, Georgia
Collaborators: Genentech, Inc.
Conditions
(from sponsor)		 Proliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabetes
Related terms Diabetes Mellitus, Diabetic Retinopathy
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov